Irritable Bowel Syndrome Therapeutic Pipeline Industry Review H2 2014 -- DALLAS, November 2, 2014 /PRNewswire/ -- RnRMarketResearch.com adds Irritable Bowel Syndrome - Pipeline Review, H2 2014 market research report to its store. The report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. Irritable bowel syndrome is a symptom-based diagnosis characterized by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits. As a functional gastrointestinal disorder (FGID), IBS has no known organic cause. Diarrhea or constipation may predominate, or they may alternate (classified as IBS-D, IBS-C, or IBS-A, respectively). Historically a diagnosis of exclusion, a diagnosis of IBS can now be made on the basis of symptoms alone, in the absence of alarm features such as age of onset greater than 50 years, weight loss, gross hematochezia, systemic signs of infection or colitis, or family history of inflammatory bowel disease. Onset of IBS is more likely to occur after an infection (postinfectious IBS-PI), or a stressful life event, but varies little with age. Complete Report with Table of Content @ http://www.rnrmarketresearch.com/irritable-bowel-syndrome-pipeline-review-h2-2014-market-report.html . Irritable bowel syndrome has no direct effect on life expectancy. It is, however, a source of chronic pain, fatigue, and other symptoms, and contributes to work absenteeism. The high prevalence of IBS and significant effects on quality of life make it a disease with a high social cost. A proportion of IBS patients may develop depression, so are more likely to commit suicide. Proposed factors for increased suicide rate in IBS patients include perceived hopelessness and poor quality of services. Irritable Bowel Syndrome - Companies Involved in Therapeutics Development: AstraZeneca PLC, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Ono Pharmaceutical Co., Ltd., SK Chemicals Co., Ltd., Teva Pharmaceutical Industries Limited, A. Menarini Industrie Farmaceutiche Riunite Srl, AlbireoPharma, Lexicon Pharmaceuticals, Inc., Yuhan Corporation, Alba Therapeutics Corporation, Ironwood Pharmaceuticals, Inc., Rottapharm SpA, Tioga Pharmaceuticals, Inc., Synthetic Biologics, Inc., Drais Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Protagonist Therapeutics Inc., Alfa Wassermann S.p.A, RaQualia Pharma Inc., Furiex Pharmaceuticals, Inc., Hanmi Pharmaceuticals, Co. Ltd., X-BODY BioSciences, Inc., ImmusanT, Inc., AltheRx Pharmaceuticals, Inc., GIcare Pharma Inc, Dong-A Socio Group. Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235038 . Drug Profiles (Product Description, Mechanism of Action and R&D Progress) in Irritable Bowel Syndrome: Rifaximin, eluxadoline, ibodutant, linaclotide, asimadoline, dexloxiglumide, rifaximin, tenapanor hydrochloride, plecanatide, solabegron hydrochloride, elobixibat, ONO-2952, LX-1033, ASP-7147, (Bacillus subtilis + mosapride + Streptococcus faecium), DSP-6952, SKI-3246, SYN-010, larazotide acetate, DA-6886, YH-12852, MDT-006, RQ-00202730, RQ-00310941, GIC-1001, Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine, ASP-1017, TAK-480, Nexvax-2, Synthetic Peptides for Gastrointestinal Disorders, Monoclonal Antibody to Inhibit M3 for Irritable Bowel Syndrome, SYN-007 and Peptides for Irritable Bowel Syndrome and Inflammatory Bowel Disease. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Inquire before Buying @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=235038 . This is a premium report priced at US$2000 for a single user License. The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome The report reviews key players involved in the therapeutics development for Irritable Bowel Syndrome and enlists all their major and minor projects A review of the Irritable Bowel Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Coverage of the Irritable Bowel Syndrome pipeline on the basis of target, MoA, route of administration and molecule type Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics Browse more reports on Gastrointestinal therapeutics Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/gastrointestinal-therapeutics . Contact: Ritesh Tiwari TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252 Tel: +1-888-391-5441 sales@rnrmarketresearch.com